Welcome to Scandinavian Biopharma,

We are an entrepreneurial company specialised in global vaccine development, manufacturing, registration and commercialization of biopharmaceutical products. Our team has previously successfully developed, manufactured, registered and globally l[...]

Scandinavian Biopharma signs a joint procurement with EU commission to supply diphtheria antitoxin

Scandinavian Biopharma and The European Commission’s Health Emergency Preparedness and Response Authority (HERA) has signed a joint procurement framework contract for the supply of diphtheria antitoxin. Eight Member States are participating in[...]

Scandinavian Biopharma reports 27% growth for 2023 and initiates a pre-study ahead of phase III

Scandinavian Biopharma is pleased to announce another year of significant growth. For the full year 2023, the revenue increased by over 33 MSEK, corresponding an organic growth of 27%. The total revenue for 2023 amounted to 154 MSEK. The ETEC[...]